AUTOLUS
LIVE

Serial Number

79338455

Owner

Autolus Limited

Attorney

Rebecca Liebowitz

Filing Date

Mar 2, 2022

Add to watchlist:

No watchlists yet
View on USPTO

AUTOLUS Trademark

Serial Number: 79338455 • Registration: 7095476

AUTOLUS is a trademark filed by Autolus Limited on March 2, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Autolus Limited (7 trademarks)

The MediaWorks

Entity Type: 99

Trademark Details

Filing Date

March 2, 2022

Registration Date

July 4, 2023

Published for Opposition

April 18, 2023

Cancellation Date

April 16, 2025

Goods & Services

Medical services; veterinary services; medical and veterinary services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes namely, medical services relating to the removal, treatment and processing of human and animal cells; medical and veterinary services in the nature of reinsertion of cells into human and animal patients; providing advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies

Scientific and technological services and research and design relating thereto, namely medical research, scientific research, analysis and testing in the field of human and animal cell and gene therapies, pharmaceutical product development, research and development of new products; industrial analysis and research services in the field of cell and gene therapies ; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services

Medical and veterinary preparations for therapeutic purposes, for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical preparations for cell therapy, for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical preparations for gene therapy, for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical preparations for the treatment of cancer; cells for medial or clinical use, namely cells featuring chimeric antigen receptors (CAR) and therapeutic preparations thereof, for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; antibodies for medical purposes for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors, namely, culture media for cultivating and augmentation of human and animal cells; preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Feb 12, 2026 DENA
DEATH OF INTERNATIONAL REGISTRATION
Feb 12, 2026 DETH
NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Nov 15, 2025 DENA
DEATH OF INTERNATIONAL REGISTRATION
Nov 15, 2025 DETH
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 31, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 6, 2023 FICS
FINAL DISPOSITION PROCESSED
Oct 5, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 4, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 4, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 4, 2023 R.PR
NOTIFICATION PROCESSED BY IB
May 9, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 18, 2023 NPUB
PUBLISHED FOR OPPOSITION
Apr 18, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 5, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 5, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 29, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 15, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 13, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 11, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 11, 2023 TROA
REFUSAL PROCESSED BY IB
Mar 5, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 9, 2023 RFCS
REFUSAL PROCESSED BY MPU
Feb 8, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 15, 2022 RFCR
NON-FINAL ACTION WRITTEN
Dec 14, 2022 CNRT
ASSIGNED TO EXAMINER
Dec 14, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 19, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 15, 2022 NWOS
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Apr 14, 2022 SDRC